Praxis Precision Medicines

#Epilepsy #CNS Disorders #Genetic Neurology #Movement Disorders

Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into precision therapies for central nervous system (CNS) disorders, with a focus on epilepsy and broader neuroscience.

Company Info

Sector:Small Molecule Pharma

Headquarters:Boston, Massachusetts, United States

Founded:2020

Website:praxismedicines.com/

Upcoming Milestones & Key Dates

2026-09-29

PDUFA

Relutrigine PDUFA (FDA)

2026-Q4

Regulatory

PRAX-080 IND submission

Clinical Development Pipeline

Relutrigine (PRAX-222)

Target: Nav1.1 modulator

SCN1A-related developmental and epileptic encephalopathy

Preclinical

Phase 1

Phase 2

Phase 3

Approved

PRAX-080

Target: Sodium channel modulator

Multiple epilepsy syndromes (PCDH19, SCN1A, SCN8A)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

PRAX-090

Target: T-type calcium channel

Essential tremor

Preclinical

Phase 1

Phase 2

Phase 3

Approved

FDA hits Praxis with 3-month delay for epilepsy drug verdict ↗

The FDA has pushed back its PDUFA decision date for Praxis Precision Medicines' epilepsy drug relutrigine by approximately three months, according to analyst commentary.

Leadership Team

Marcio Souza

President and Chief Executive Officer (since April 2020)

Dr. Orrin Devinsky

Head of Clinical Strategy

Dr. Megan Petrou

Head of Research & Development

Careers & Job Openings

See all open roles

Careers

Boston, Massachusetts, United States

Apply Now →